Research progress on the application of LAG-3 and its inhibitors in cancer immunotherapy
10.3872/j.issn.1007-385x.2019.09.002
- VernacularTitle:LAG-3及其抑制剂在肿瘤免疫治疗中应用的研究进展
- Author:
CHEN Xiuxiu
;
YU Xiaojie
;
ZHOU Lijun
- Publication Type:Journal Article
- Keywords:
lymphocyte activatinggene3(LAG-3);
tumor;
immunotherapy;
immunecheckpoint inhibitor;
programmed death protein-1 (PD-1);
cytotoxic T-lymphocyte antigen-4 (CTLA-4)
- From:
Chinese Journal of Cancer Biotherapy
2019;26(9):941-947
- CountryChina
- Language:Chinese
-
Abstract:
Lymphocyte-activation gene 3 (LAG-3), also known as CD223, is a 498-amino-acid type I transmembrane protein encoded by LAG-3 gene, which consists of extracellular, transmembrane and intracellular regions.LAG-3 negatively regulates T lymphocyte by binding extracellular domain to ligand, thus avoiding autoimmunitycaused by T cell over-activation. Like programmed cell death 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4), LAG-3 is an important immune checkpoint in vivo and plays a balanced regulatory role in human immune system.Tumor cells escape the surveillance of the immune system by over-expressing LAG-3 ligand. With the development in research of immune checkpoints, LAG-3 has become a new generation of immunotherapy targets after PD-1 and CTLA-4. This article reviews the structure and function of LAG-3 and the application of its inhibitors in tumor immunotherapy, in order to provide reference for the further study of LAG-3.
